No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for OKYO Pharma Limited (OKYO) stock was $1.49 as of Oct 6, 2026, 1:43 PM EDT, up 1.02% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -28.2% · 3-year avg -16.2%/yr
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease.
Biotechnology · London, GL
Next Earnings Date
Dec 2, 2026
57 days away
EPS Estimate
-0.06
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
$-0.08
Revenue
$0.00
vs Estimate
$0.00
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OKYO | $56.98M | $1.49 | +1.02% | -28.18% | N/A | N/A | N/A |
| 2TLPH | $57.09M | $1.10 | -5.17% | +21.99% | -43.65% | -34.23% | vs OKYO |
| 3INKT | $57.69M | $11.58 | -5.08% | -18.69% | N/A | N/A | vs OKYO |
| 4PDSB | $57.88M | $1.03 | -13.75% | +17.56% | -39.13% | -40.75% | vs OKYO |
| 5BOLD | $58.66M | $2.61 | +0.38% | +110.63% | N/A | N/A | vs OKYO |
| 6CNTB | $59.60M | $0.95 | +5.42% | -39.59% | -47.22% | N/A | vs OKYO |
forward FY estimate
N/A
Consensus Rating
Based on 3 analysts
Average Price Target
$8.33
+461.2% upside
Low
$5.00
Current
$1.49
High
$13.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $-0.18 | $-0.14 | $-0.08 | 1 |
| FY 2028 | $-0.69 | $-0.41 | $-0.12 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2028 | $11.00M | $11.00M | $11.00M | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
